

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
13 June 2024 (13.06.2024)



(10) International Publication Number
WO 2024/124182 A1

(51) International Patent Classification:

A61K 9/20 (2006.01) A61K 45/06 (2006.01)
A61K 31/437 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2023/083202

(22) International Filing Date:

08 December 2023 (08.12.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/431,515 09 December 2022 (09.12.2022) US

(71) Applicant: **OLEMA PHARMACEUTICALS, INC.**
[US/US]; 780 Brannan Street, San Francisco, California
94103 (US).

(72) Inventors: **GULLAPALLI, Rampurna Prasad**; c/o Olema Pharmaceuticals, Inc., 780 Brannan Street, San Francisco, California 94103 (US). **MYLES, David, C.**; c/o Olema Pharmaceuticals, Inc., 780 Brannan Street, San Francisco, California 94103 (US). **ZHANG, Jing Jim**; c/o Olema Pharmaceuticals, Inc., 780 Brannan Street, San Francisco,

California 94103 (US). **EMORY, Stephanie, Marie, Noe**; c/o Olema Pharmaceuticals, Inc., 780 Brannan Street, San Francisco, California 94103 (US). **BABAR, Digvijay**; c/o Olema Pharmaceuticals, Inc., 780 Brannan Street, San Francisco, California 94103 (US). **LI, Yongqiang**; c/o Olema Pharmaceuticals, Inc., 780 Brannan Street, San Francisco, California 94103 (US).

(74) Agent: **SHINALL, Michael, A.** et al.; Choate, Hall & Stewart LLP, Two International Place, Boston, Massachusetts 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: DOSAGE FORMS OF AN ESTROGEN RECEPTOR ANTAGONIST





FIG. 1

(57) Abstract: The present disclosure provides unit dosage forms comprising Compound 1 (I) Compound 1 or a pharmaceutically acceptable salt thereof, that are useful for treatment of estrogen receptor mediator diseases, disorders, and conditions. The presently described unit dosage forms are suitable for oral administration.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*